Evonik Shares: A Potential Windfall from US Tariff Revisions

Evonik explores reclaiming millions in US tariffs after a Supreme Court decision, offering a potential one-time financial boost as investors await key 2025 results.

The German specialty chemicals company Evonik is actively exploring the possibility of reclaiming millions in previously paid US tariffs, following a landmark court ruling. This process could generate an unexpected, though limited, financial boost for the firm.

Evaluating a Potential Refund

Interim CFO Claus Rettig confirmed on February 26 that the company is assessing its options for recovering certain duties. The potential sum involved is described as a "low double-digit million euro" amount. This evaluation was triggered by a February 20, 2026, decision from the US Supreme Court, which retroactively deemed a significant portion of tariffs levied under an older statute unlawful. Evonik is now examining whether it qualifies for reimbursements under this new legal precedent.

Limited Operational Exposure Provides Context

While a potential cash recovery is notable, Evonik has consistently described its direct exposure to US trade measures as manageable. This is due to a strategic and pragmatic operational setup: a substantial portion of the products it sells in the United States is manufactured locally. This significantly insulates the company's core operations from the impact of cross-border duties.

The market's recent focus, however, has been elsewhere. The stock closed today's session at €14.73, marking a daily decline of 1.60%. Over a 12-month period, the shares remain down by 23.14%. The technical picture appears weak, underscored by a notably low Relative Strength Index (RSI) reading of 15.8.

Upcoming Financials Take Center Stage

Investor attention is now shifting to the next key catalyst: the release of Evonik's complete and audited annual results for 2025, scheduled for March 4, 2026. These figures will provide a clearer picture of the company's fundamental health. Earlier in February, Evonik also announced an adjustment to its dividend policy, aimed at enhancing financial flexibility.

In summary, the potential tariff repayment represents a possible one-time positive factor. Nevertheless, the imminent publication of the 2025 financial statements this coming Wednesday is set to be the next substantive test for the equity.